Architect hbeag assay

Clinical data were collected at the time of initiating NA treatment and included age, sex, and the presence of LC. Baseline laboratory variables included aspartate transaminase (AST), alanine transaminase (ALT), bilirubin, creatinine, albumin, platelet counts, white blood cell counts, international normalized ratio (INR), HBV DNA levels, HBeAg, and quantitative HBsAg levels. The presence of LC was diagnosed using methods such as liver biopsy, abdominal ultrasonography (US), computed tomography (CT), magnetic resonance imaging (MRI), or fibroscan. HBV DNA levels were ascertained using a real-time polymerase chain reaction (PCR) assay (Abbott Laboratories, Abbott Park, IL, USA), with a detection threshold of 10 IU/mL. Quantitative HBsAg level measurements were performed using commercial immunoassays (Abbott Laboratories, Abbott Park, IL, USA). HbeAg levels were also quantified using the Architect HbeAg assay (Abbott Laboratories, Abbott Park, IL, USA). The assay results were validated with a reference standard (100 PEIU/mL) obtained from the Paul Ehrlich Institute (Langen, Germany) [13 (link)].

Fasting vein blood was collected for laboratory tests within 1 week of liver biopsy. Hyaluronic acid (HA), laminin, type III procollagen (PCIII), and type IV collagen (IV-C) were determined using Autodesk Chemiluminescent Immunoassay Analyzer (Yantai, China) and reagents from Beijing Yuande Bio-Medical Engineering Co., Ltd. (Beijing, China). HBV DNA quantification was performed using Abbott RealTime HBV assay with the Abbott m2000 SystemDNA reagents (Abbott Molecular Inc., Des Plaines, IL, USA) and ABI7500 Quantitative Cycler (ABI, USA). HBsAg was quantitatively determined by chemiluminescent microparticle immunoassay (CMIA) of ARCHITECT HBsAg assay (Abbott Ireland, Sligo, Ireland). HBeAg and anti-HBc were determined by CMIA of ARCHITECT HBeAg assay (Abbott GmbH & Co. KG, Wiesbaden, Germany) and anti-HBc II assay (Abbott GmbH & Co. KG, Wiesbaden, Germany), respectively, and the ratios of the sample to the cutoff values (S/CO) were used as HBeAg and anti-HBc levels, respectively.

Hepatitis B e antigen (HBeAg) was detected from cell culture supernatants on an Architect i1000sr instrument (Abbott, Wiesbaden, Germany) using a diagnostic qualitative chemiluminescent microparticle immunoassay (CMIA, Architect HBeAg Assay, off-label, Abbott, Green Oaks, IL, USA). Qualitative results (detected/not detected) and signal-to-cutoff ratios (S/CO) were recorded for each measurement.